In just a couple of days, the oncology
community of physicians, scientists and researchers,
allied medical professionals, advocates, the
pharmaceutical and biotechnology industry, and others,
will gather in Chicago, for the 49th Annual Meeting of
the American Society of Clinical Oncology (ASCO).
This annual meeting will bring together 30,000 cancer
specialists from around the world, presenting
educational sessions, posters, and as many as 5000
abstracts, sharing data and the results of clinical
trials and research on a global scale. It is at
such meetings where shared discoveries will often lead
to new standards and practice-changing patient care,
innovation, and hope.
ASCO 2013 marks the 15th Year that Vital Options
has been privileged to be amongst selected media
reporting from the Annual Meeting. In 1998, when
the Annual Meeting last took place in Los Angeles,
The Group Room?, was the first radio
show allowed to broadcast live from the ASCO
floor. That was a true milestone for Vital Options
and demonstrated the commitment of ASCO on behalf of
patient outreach and partnership. Please visit
ASCO’s oncologist-approved cancer information website
at Cancer.net.
The Group Room and other Vital
Options programs are now in a video format, but we
continue reporting on the latest scientific findings,
clinical advances, human interest stories, and the
progress being made by cancer advocates throughout the
country.
Advocacy In Action? at ASCO
has expanded to three topics, the Genomics of
Metastatic Cancer, Palliative Care, and
the latest Lung Cancer Treatment Guidelines &
Molecular Testing. This show allows leaders
of the advocate community to engage in discussions with
academic oncologists, exploring how advocacy and science
intertwine, and taking on issues that really matter from
the patient’s point of view.
This year’s ASCO meeting theme is Building
Bridges to Conquer Cancer. We hope to bring
you back some great videos showing how the bridges are
truly being connected through our growing knowledge and
understanding of molecular biology and cancer, and the
importance of integrative oncology care!
Until soon
then.
Best of
wishes,
A
THREE-PART ADVOCATE
ROUNDTABLE
VIDEO SERIES
AT ASCO
2013
Vital Options
International presents Advocacy In Action,
bringing together cancer advocacy leadership to
address:
Genomics Of
Metastatic Cancer
Palliative
Care
Lung
Cancer Treatment Guidelines & Molecular
Testing
Sunday,
June 2 | 11:00am – 1:30pm
Hyatt
McCormick Place
Room
CLARK AB
11:00-11:30:
Meet & Greet Reception with
Snacks
11:30-11:50:
Genomics of Metastatic Cancer
11:55-12:50:
Palliative Care
12:55-1:30:
Lung Cancer Treatment Guidelines & Molecular
Testing
Genomics
of Metastatic Cancer
Heinz-Josef
Lenz, MD, FACP, Associate Director for Clinical
Research and Co-Leader of the GI Oncology Program, USC
Norris Comprehensive Cancer Center
Shirley
Mertz, President, Metastatic Breast Cancer
Network
Palliative
Care
Jamie
H. Von Roenn, MD – Professor of Medicine,
Division of Hematology/Oncology; Feinberg School of
Medicine, Northwestern University; Robert H. Lurie
Comprehensive Cancer Center; Chair, ASCO thematic
meeting—Palliative Care in Oncology; Chair of the ASCO
Leadership Development Program, Chair of the ASCO
Professional Development Committee; Co-Chair of the
AACR-ASCO Clinical Trials Workshop, and Chair of the
2014, ASCO thematic meeting—Palliative Care in
Oncology
Linda
House, RN, BSN, MSM – Executive Vice President
of External Affairs, Cancer Support Community, and
C-Change (for which she Co-Chairs the Guidance
Subcommittee of the C-Change Assuring Value in Cancer
Care Advisory Committee)
Helen
Miller, LCSW – CEO, CancerCare
Shirley
Mertz, President, Metastatic Breast Cancer
Network
Lung
Cancer Treatment Guidelines & Molecular
Testing
David
R. Spigel, MD – Director, Lung Cancer Research
Program at Sarah Cannon Research Institute and a Medical
Oncologist at Tennessee Oncology, PLLC, Nashville,
TN
Ming
S. Tsao, MD, FRCPC – Princess Margaret Cancer
Centre, Toronto, Canada
Andrea
Stern Ferris – President, LUNGevity
Kim
Norris – Founder/President, Lung Cancer
Foundation of America
Regina
Vidaver, PhD – Executive Director, National
Lung Cancer Partnership
Support for The Group
Room and Advocacy In Action at ASCO 2013 is made
possible in part by:
These
interviews were filmed with doctors around the
globe at the European Society for Medical
Oncology (ESMO) 2012 Annual Meeting in
Vienna.
Each
doctor was asked the following question:
Data
in advanced cancer shows that palliative care
given concurrently with standard anti-cancer
treatment; extends life and reduces
hospitalizations. How should this evidence
from the Temel Study be integrated in oncology
care today?
These
are their answers.
The Group Room and
Advocacy In Action video content can now be
found on the new Avva Ask
App!
Avva Ask? is the
essential app for cancer patients. It’s a voice
recorder and health information organizer that’s
simple, free, and easy to use. Record voice memos
or entire visits with your doctor quickly and
easily, and play them back at any time. For each
treatment or other health event you enter into the
app – whether it’s a biopsy, chemotherapy, or
other treatment – you can access educational
materials, see tips from other users on managing
side effects, and make a list of questions for
your doctor about that treatment based on our
suggestions, and note down answers, whether typed
or audio recorded.
Avva Ask? is the
second mobile app developed by Avva, founded by
Stanford University graduate students with the
guidance of physicians at the Stanford Cancer
Institute. The app does not require you to sign up
for an account or submit any personal information,
and all information you save is secure and
anonymous.To learn more or download the
application, click here.
Coming Up Next …
American Society of Clinical
Oncology (ASCO), European
Multidisciplinary Cancer Congress (EMCC), World
Conference on Lung Cancer (WCLC), San Antonio Breast Cancer Symposium
(SABCS) and American Society of
Hematology (ASH).12-month
corporate memberships to help
support all of our content year-round, as well as
individual conference sponsorships are
available.
For more
information on the memberships/conference
packages, production services and advocacy
relations please contact, Terry
Wilcox at twilcox@vitaloptions.org.
For more
information on sponsorships, corporate relations,
and other programming opportunities, please
contact, Selma Schimmel
at
sschimmel@vitaloptions.org.
About Vital Options
International
Founded in 1983 as the first
organization for young adults with cancer, Vital
Options is now a cancer communications
organization, serving all age groups and cancer
types with a mission to facilitate a global cancer
dialogue. Headquartered in Southern
California, its European program is based in
France at the American Hospital of Paris, with
production partners at Radio Marsden, the Royal
Marsden Hospital, London, UK.
VITAL
OPTIONS INTERNATIONAL
Advocacy In Action? at
ASCO
2013
MAY 2013
Worldwide View On Palliative Care
Video
Dear Silvia,
Selma
Schimmel Founder &
CEO
In just a couple of days, the oncology
community of physicians, scientists and researchers,
allied medical professionals, advocates, the
pharmaceutical and biotechnology industry, and others,
will gather in Chicago, for the 49th Annual Meeting of
the American Society of Clinical Oncology (ASCO).
This annual meeting will bring together 30,000 cancer
specialists from around the world, presenting
educational sessions, posters, and as many as 5000
abstracts, sharing data and the results of clinical
trials and research on a global scale. It is at
such meetings where shared discoveries will often lead
to new standards and practice-changing patient care,
innovation, and hope.
ASCO 2013 marks the 15th Year that Vital Options
has been privileged to be amongst selected media
reporting from the Annual Meeting. In 1998, when
the Annual Meeting last took place in Los Angeles,
The Group Room?, was the first radio
show allowed to broadcast live from the ASCO
floor. That was a true milestone for Vital Options
and demonstrated the commitment of ASCO on behalf of
patient outreach and partnership. Please visit
ASCO’s oncologist-approved cancer information website
at Cancer.net.
The Group Room and other Vital
Options programs are now in a video format, but we
continue reporting on the latest scientific findings,
clinical advances, human interest stories, and the
progress being made by cancer advocates throughout the
country.
Advocacy In Action? at ASCO
has expanded to three topics, the Genomics of
Metastatic Cancer, Palliative Care, and
the latest Lung Cancer Treatment Guidelines &
Molecular Testing. This show allows leaders
of the advocate community to engage in discussions with
academic oncologists, exploring how advocacy and science
intertwine, and taking on issues that really matter from
the patient’s point of view.
This year’s ASCO meeting theme is Building
Bridges to Conquer Cancer. We hope to bring
you back some great videos showing how the bridges are
truly being connected through our growing knowledge and
understanding of molecular biology and cancer, and the
importance of integrative oncology care!
Until soon
then.
Best of
wishes,
A
THREE-PART ADVOCATE
ROUNDTABLE
VIDEO SERIES
AT ASCO
2013
Vital Options
International presents Advocacy In Action,
bringing together cancer advocacy leadership to
address:
Genomics Of
Metastatic Cancer
Palliative
Care
Lung
Cancer Treatment Guidelines & Molecular
Testing
Sunday,
June 2 | 11:00am – 1:30pm
Hyatt
McCormick Place
Room
CLARK AB
11:00-11:30:
Meet & Greet Reception with
Snacks
11:30-11:50:
Genomics of Metastatic Cancer
11:55-12:50:
Palliative Care
12:55-1:30:
Lung Cancer Treatment Guidelines & Molecular
Testing
Genomics
of Metastatic Cancer
Heinz-Josef
Lenz, MD, FACP, Associate Director for Clinical
Research and Co-Leader of the GI Oncology Program, USC
Norris Comprehensive Cancer Center
Shirley
Mertz, President, Metastatic Breast Cancer
Network
Palliative
Care
Jamie
H. Von Roenn, MD – Professor of Medicine,
Division of Hematology/Oncology; Feinberg School of
Medicine, Northwestern University; Robert H. Lurie
Comprehensive Cancer Center; Chair, ASCO thematic
meeting—Palliative Care in Oncology; Chair of the ASCO
Leadership Development Program, Chair of the ASCO
Professional Development Committee; Co-Chair of the
AACR-ASCO Clinical Trials Workshop, and Chair of the
2014, ASCO thematic meeting—Palliative Care in
Oncology
Linda
House, RN, BSN, MSM – Executive Vice President
of External Affairs, Cancer Support Community, and
C-Change (for which she Co-Chairs the Guidance
Subcommittee of the C-Change Assuring Value in Cancer
Care Advisory Committee)
Helen
Miller, LCSW – CEO, CancerCare
Shirley
Mertz, President, Metastatic Breast Cancer
Network
Lung
Cancer Treatment Guidelines & Molecular
Testing
David
R. Spigel, MD – Director, Lung Cancer Research
Program at Sarah Cannon Research Institute and a Medical
Oncologist at Tennessee Oncology, PLLC, Nashville,
TN
Ming
S. Tsao, MD, FRCPC – Princess Margaret Cancer
Centre, Toronto, Canada
Andrea
Stern Ferris – President, LUNGevity
Kim
Norris – Founder/President, Lung Cancer
Foundation of America
Regina
Vidaver, PhD – Executive Director, National
Lung Cancer Partnership
Support for The Group
Room and Advocacy In Action at ASCO 2013 is made
possible in part by:
These
interviews were filmed with doctors around the
globe at the European Society for Medical
Oncology (ESMO) 2012 Annual Meeting in
Vienna.
Each
doctor was asked the following question:
Data
in advanced cancer shows that palliative care
given concurrently with standard anti-cancer
treatment; extends life and reduces
hospitalizations. How should this evidence
from the Temel Study be integrated in oncology
care today?
These
are their answers.
The Group Room and
Advocacy In Action video content can now be
found on the new Avva Ask
App!
Avva Ask? is the
essential app for cancer patients. It’s a voice
recorder and health information organizer that’s
simple, free, and easy to use. Record voice memos
or entire visits with your doctor quickly and
easily, and play them back at any time. For each
treatment or other health event you enter into the
app – whether it’s a biopsy, chemotherapy, or
other treatment – you can access educational
materials, see tips from other users on managing
side effects, and make a list of questions for
your doctor about that treatment based on our
suggestions, and note down answers, whether typed
or audio recorded.
Avva Ask? is the
second mobile app developed by Avva, founded by
Stanford University graduate students with the
guidance of physicians at the Stanford Cancer
Institute. The app does not require you to sign up
for an account or submit any personal information,
and all information you save is secure and
anonymous.To learn more or download the
application, click here.
Coming Up Next …
American Society of Clinical
Oncology (ASCO), European
Multidisciplinary Cancer Congress (EMCC), World
Conference on Lung Cancer (WCLC), San Antonio Breast Cancer Symposium
(SABCS) and American Society of
Hematology (ASH).12-month
corporate memberships to help
support all of our content year-round, as well as
individual conference sponsorships are
available.
For more
information on the memberships/conference
packages, production services and advocacy
relations please contact, Terry
Wilcox at twilcox@vitaloptions.org.
For more
information on sponsorships, corporate relations,
and other programming opportunities, please
contact, Selma Schimmel
at
sschimmel@vitaloptions.org.
About Vital Options
International
Founded in 1983 as the first
organization for young adults with cancer, Vital
Options is now a cancer communications
organization, serving all age groups and cancer
types with a mission to facilitate a global cancer
dialogue. Headquartered in Southern
California, its European program is based in
France at the American Hospital of Paris, with
production partners at Radio Marsden, the Royal
Marsden Hospital, London, UK.
Giovedì 17 novembre, presso la discoteca torinese The Big Club, si è tenuta una serata di beneficenza a favore dell’Associazione Walce Onlus On Thursday, November 17, at the disco The Big Club in Torino had place a pleasant evening organized for the aid of charity with the aim to support WALCE.
WALCE Onlus (Women Against Lung Cancer in Europe – Donne Contro il Tumore del Polmone in Europa), è un’associazione “a respiro europeo” per la lotta contro le neoplasie toraciche.
Nata nel 2006 con l’obiettivo di sensibilizzare la popolazione femminile rispetto all’aumento di incidenza e mortalità del tumore del polmone anche tra le donne, oggi WALCE informa, educa e supporta i pazienti affetti da questa patologia durante il percorso di malattia e realizza campagne nazionali di prevenzione primaria e di sensibilizzazione rispetto ai danni arrecati dall’abitudine tabagica.
Il 24 settembre 2006 nasce a Torino l’Associazione WALCE Onlus
Women Against Lung Cancer in Europe
“L’idea di fondare questa associazione per i pazienti nasce da un’iniziativa italo-spagnola: la dottoressa Enriqueta Felip e io facciamo infatti parte del Comitato Scientifico di una ben consolidata Associazione americana creata alcuni anni fa da un gruppo di oncologhe statunitensi. Questa Associazione, National Lung Cancer Partnership conta ormai molti soci e sostiene programmi di ricerca ad alto valore scientifico. L’esigenza di una associazione europea nasce dalla necessità di creare un gruppo europeo che meglio rispecchi le caratteristiche della popolazione e si avvicini ai fabbisogni dei pazienti.”
Prof.ssa Silvia Novello
Presidente dell’Associazione
WALCE (Women Against Lung Cancer in Europe) is a non profit organization
initiated in 2006 by Dr Silvia Novello, current President of WALCE and a Spanish colleague, Dr Enriqueta Felip, both members of the Scientific Committee of “National Lung Cancer Partnership”, with the primary aim to make women aware about the significant increase of lung cancer in female gender and to provide and disseminate information about the disease in terms of prevention, diagnosis and treatment focusing the attention on the leading role of women as caregivers.
WALCE is involved in advocacy, education and support initiatives
for people affected from lung cancer and for their families.
The Scientific Committee of WALCE is involved in research projects concerning the better definition of gender differences in lung cancer and in primary prevention projects, trough educational materials designed and produced specifically by the Association. WALCE works both at national and international level against the fight of lung cancer, attempting to make the Public Opinion, the Government and Media aware on all issues related to lung cancer, also using a good net of contacts and the cooperation with other associations well established in this field.
L’Association WALCE née à Turin le 24 septembre 2006
L’idée de fonder une Association pour les patients née à partir d’une initiative italo-espagnole: la Doctoresse Enriqueta Felip et moi-même faisons partie du Comité Scientifique d’une Association américaine, aujourd’hui solidement ancrée, créée il y a quelques années par un groupe d’oncologues américains. Cette association, National Lung Cancer Partenership compte aujourd’hui de nombreux membres et soutient les programmes de recherche à haute valeur scientifique. L’exigence d’une association européenne naît de la nécessité de créer un groupe européen qui reflète mieux les caractéristiques de la population et qui s’intéresse à la demande et aux exigences des patients.
In questo spazio, costantemente aggiornato, vi segnaliamo tutti i congressi, workshop e corsi che affrontano problematiche correlate all’Oncologia Polmonare. Ogni anno, molti sono gli eventi scientifici di questo tipo che vengono organizzati in Italia e all’estero. Per tutti i medici, i ricercatori, gli infermieri e gli operatori sanitari, che quotidianamente prestano il proprio servizio in campo oncologico, essere presenti in questi appuntamenti è importante per avere la possibilità di aggiornare e confrontare le proprie conoscenze con altri professionisti, provenienti da ogni parte del mondo.
2021
MARZO 2021
EVENTO PATROCINATO da WALCE
BUILDING BRIDGES to interconnect people
First fully digital meeting in clinical oncology
30-31 marzo / 1° aprile 2021
28-29-30 settembre 2021 Scarica la brochure (PDF)
EVENTO PATROCINATO da WALCE
DALLA PREVENZIONE ALLA TERAPIA DELLA MALATTIA AVANZATA (NONOSTANTE COVID-19)
IV Conferenza di Oncologia Polmonare
Bari, 9-10 novembre 2020 Scarica la brochure in formato PDF
EVENTO PATROCINATO da WALCE
ANIMALI SOCIALI E BENESSERE GLOBALE:
il miglioramento della qualità della vita attraverso animali natura e territorio
Grugliasco (TO), 15 novembre 2019 Scarica la brochure in formato PDF
EVENTO PATROCINATO da WALCE
III Convegno di Oncologia Integrata “Genetica e Medicina Integrata in Oncologia e Psiconcologia: come utilizzare la mappa del nostro DNA per traguardi di prevenzione e salute”
Modena, 3 marzo 2019 www.convegnoncologiaintegrata.it
GENNAIO 2019
EVENTO PATROCINATO da WALCE
L’immunoterapia nei trattamenti multidisciplinari dei tumori del rene, della vescica, della testa e del collo
Roma, 25-26 gennaio 2019 Scarica la brochure in formato PDF
EVENTO PATROCINATO da WALCE
Approfondimenti sulla stesura di un protocollo di ricerca
Orbassano (TO), 6 dicembre 2017 Scarica la brochure in formato PDF
GIUGNO 2017
Congresso Nazionale della Pneumologia Italiana – XLIV AIPO “Progresso e Innovazione Tecnologica in Pneumologia”
Bologna, 10 – 13 giugno 2017 pneumologia2017.it
L’IMMUNOTERAPIA, PRIMO APPUNTAMENTO PER IL FARMACISTA OSPEDALIERO,
IL POLMONE: INNOVAZIONE, EFFICACIA E SOSTENIBILITÀ
Torino, 29 marzo 2017 Scarica il programma in formato PDF
PINK LUNG CANCER 2
DIAGNOSI E TERAPIA DEL NSCLC: discutere con esperti in rosa informazioni generali
Lecce, 3 marzo 2016 Scarica il programma in formato PDF
IL TRIANGOLO ONCOLOGICO (tra BIOLOGIA, CLINICA e RICERCA)
Discussione del miglior lavoro scientifico pubblicato in ambito biologico e in ambito clinico nei Big Killers
Vercelli, 31 gennaio 2015 Scarica il programma in formato PDF
XVII Congresso Nazionale AIOM
Roma, 23-25 ottobre 2015 congresso.aiom.it
In this section you can find a wide range of events. We’ve indicated congresses, workshops and refresher courses focusing on topics relating to Pulmonary Oncology and Thoracic Surgery. Every year there are many scientific events in Italy and abroad for doctors, investigators, nurses and health professionals who daily work in this field. It should be important to be present at these meetings to update one’s knowledges and share them with other professionals coming from every part of the world.
Dans cet espace, constamment mis à jour, nous vous signalons toutes les conférences, les ateliers et les cours qui traitent d’Oncologie Pulmonaire. Chaque année, de nombreuses manifestations scientifiques de ce type sont organisées en Italie et à l’étranger. Pour tous les médecins, les chercheurs, les infirmiers et les professionnels de la santé qui, chaque jour, prêtent service en oncologie, il est important d’être présents à ces événements afin d’avoir la possibilité de mettre à jour et de confronter leurs connaissances avec d’autres professionnels provenant du monde entier.
In questa pagina è possibile visionare tutti i centri WALCE.
Clicca sulla mappa la località di tuo interesse, verrà visualizzato direttamente l’indirizzo di riferimento del Centro
Di seguito è possibile trovare una panoramica sui principali progetti promossi da WALCE Onlus. Per maggiori informazioni: tel. 011 9026980, info@womenagainstlungcancer.euWith your help we can support the research and the development of a European network working towards uniformity of diagnosis procedures and therapy. All the projects sustained by WALCE will be described in this space for making you to participate of your contribution in the scientific research.
Il tuo hobby può aiutare la ricerca scientifica: un oggetto da te realizzato e donato a WALCE renderà più gradevole una donazione da parte di chi accederà al nostro sito Internet.
Unisciti a noi! L’adesione al WALCE è aperta a tutti, a donne affette da tumore del polmone, alle loro famiglie, alle loro amiche, amici, a medici, infermieri, ricercatori e professionisti del settore sanitario, a tutti coloro, che come noi, vogliono che il numero di decessi dovuti a questa patologia si riduca sensibilmente.
Diventare membro WALCE è molto semplice.
Basta scaricare la scheda e rispedirla firmata a:
WALCE Onlus (Women Against Lung Cancer in Europe)
c/o SSD Oncologia Polmonare – AOU San Luigi
Regione Gonzole, 10
10043 Orbassano (TO) – Italia
Con l’adesione all’Associazione diventerai membro WALCE e, periodicamente, riceverai la Newsletter che ti aggiornerà sui progressi fatti dall’Associazione e sulle sue attività. Compatibilmente con i tuoi impegni e comunque indipendentemente da quella che è la tua professione, potrai aiutarci a far crescere WALCE e, di conseguenza a stare più vicini ai pazienti affetti da questa patologia. Ci sono tantissimi modi per contribuire alla causa e ogni tua proposta è ben accetta e verrà discussa dal Consiglio Direttivo.
Join us! Membership is open to everyone, women who suffer from lung cancer, family members and friends, to doctors, nurses, investigators, caregivers and all those people who are interested in decreasing deaths due to this disease.
Become a member is very easy. You can download the form, complete it and post it to:
WALCE (Women Against Lung Cancer in Europe)
c/o Dipartimento Oncologia Toracica – Ospedale San Luigi
Periodically, members will receive up to date news about the association’s activities. Depending on your commitments, you could contribute to the expansion of WALCE and become an emotive support for patients who suffer from this pathology. There are many ways of participating in this project and every suggestion will be extremely welcome and discussed by the Board of Directors.
Women in Europe against Lung Cancer and Smoking. International Agency for Research on Cancer (IARC) Lyon, FranceThe Women in Europe Against Lung Cancer and Smoking (WELAS) project is a 3-year project supported by the Public Health Programme of the European Commission.
Guarda il video dell’intervista al Dott. Domenico GALETTA, Istituto Tumori “Giovanni Paolo II” di Bari | “Buongiorno Regione Puglia” – puntata del 30/4/2012
In base all’aspetto che le cellule tumorali presentano all’esame microscopico, si possono distinguere due diversi tipi di tumore del polmone:
1. il carcinoma polmonare NON a piccole cellule [Expand]
è la forma più comune costituendo il 75-80% di tutti i tumori polmonari. In genere cresce e si diffonde in maniera più lenta rispetto al carcinoma polmonare a piccole cellule. Il carcinoma polmonare NON a piccole cellule viene a sua volta suddiviso in tre differenti tipi:
Carcinoma a cellule squamose (o epidermoidale o spinocellulare): è il più diffuso negli uomini. Rappresenta circa il 30% di tutti i tumori polmonari.
Adenocarcinoma: si sviluppa dalle cellule che secernono il muco bronchiale; la sua frequenza è pari al 30-40%. E’ il tumore polmonare più frequente tra chi non abbia mai fumato e tra le donne. La frequenza dell’ adenocarcinoma è in costante aumento.
Carcinoma a grandi cellule: il nome deriva dalle grandi cellule tondeggianti che si evidenziano quando si esamina un campione di biopsia al microscopio. Rappresenta circa il 15% di tutti i tumori polmonari. Negli ultimi decenni il carcinoma a cellule squamose è in diminuzione, mentre si osserva un aumento relativo degli adenocarcinomi, probabilmente in rapporto a un cambiamento nella produzione e composizione delle sigarette. [/Expand]
2. il carcinoma polmonare a piccole cellule o microcitoma[Expand]
o “a chicco d’avena”, così definito dalla caratteristica forma delle cellule. La forma a piccole cellule è nettamente più aggressiva della forma non a piccole cellule. Il microcitoma è caratterizzato da una rapida crescita e presenta maggiori probabilità di propagarsi ad altri organi. Proprio a causa di questa sua aggressività non è per lo più indicata la resezione chirurgica. Il tumore polmonare a piccole cellule risponde molto bene alla chemioterapia e alla radioterapia ma nonostante ciò la malattia è recidiva (cioè si ripresenta) a distanza di un tempo variabile da una persona all’altra, nella quasi totalità dei casi.
On the basis of the aspect shown by tumour cells when examined under the microscope we can distinguish two different types of lung cancer:
1. the NON small-cell lung cancer
it is the most common form and accounts for 75-80 per cent of all lung cancers. Generally it develops and spreads out more slowly than the small cell lung cancer.
The NON small cell lung cancer is in turn divided into three different types:
Squamous cell carcinoma (or epidermoid or spinocellular carcinoma): it is the most widespread in men and accounts for approximately 30 per cent of all lung tumours.
Adenocarcinoma: it arises from the cells secreting the bronchial mucus; its frequency is 30-40 per cent. It is the most frequent lung cancer among the nonsmokers and women.
The frequency of adenocarcinoma is constantly increasing.
Large cell carcinoma: its name derives from the round large cells appearing when a biopsy sample is examined under the microscope. It accounts for about 15 per cent of all lung cancers.
In the last few decades the squamous cell carcinoma is declining while a relative increase in adenocarcinomas is observed, probably due to a change in cigarette production and composition.
2. The small cell lung carcinoma or microcytoma or ‘oat cell’ carcinoma, so defined because of the characteristic shape of its cells. The small cell lung cancer is definitely more aggressive than the non small cell lung cancer. The microcytoma is characterised by rapid growth and is more likely to spread to other organs. Just because of its aggressivity, surgical resection is generally not indicated. The small cell lung cancer responds very well to chemotherapy and radiation therapy, but nevertheless the disease is recurrent (that is to say reappears) after a period which varies from person to person in almost all cases.
– Giuseppe Luigi BANNA, MD
Consultant Medical Oncologist
Department of Oncology
Portsmouth Hospitals University NHS Trust
Cosham, Portsmouth, PO6 3LY | United Kingdom
Tel: 02392 286000 extn: 4784
– Giuseppe BARI
– Daniela BATTISTA
Data Manager presso S.S.D. Oncologia Polmonare [EXPAND dettagli]
AOU San Luigi Gonzaga
Regione Gonzole, 10 – Orbassano (TO) | Italia
Tel.: +39-011.9026978 / e-mail: daniela.battista@unito.it [/EXPAND]
– Melissa BERSANELLI
– Samuela BINATO, MD Ospedale di Montecchio Maggiore [EXPAND dettagli]
UOC Oncologia Medica
Via Cà Rotte, 9 – Montecchio Maggiore (VI) | Italia
Tel.: +39-0444.708190 / Fax: +39-0444.708198 / e-mail: sbinato@yahoo.it [/EXPAND]
– Paolo BIRONZO, MD
AOU San Luigi Gonzaga
Regione Gonzole, 10 – Orbassano (TO) | Italia
E-mail: pbironzo@gmail.com
– Lucio, BUFFONI, MD
Direttore SC Oncologia Medica
HUMANITAS GRADENIGO – Torino | Italia
E-mail: buffonil75@gmail.com
– Annamaria CATINO, MD
I.R.C.C.S. Istituto Tumori “Giovanni Paolo II” di Bari www.oncologico.bari.it [Expand dettagli]
Unità Operativa di Oncologia Medica
Viale Orazio Flacco, 65 – Bari | Italia
Tel.: +39-080.5555442 / Fax: +39-080.5555418 / e-mail: a.catino@oncologico.bari.it [/EXPAND]
– Fabiana CECERE, MD
S.C. Oncologia Medica 1
Istituto Nazionale Tumori Regina Elena
Via Elio Chianesi, 53 – Roma | Italia
Tel 39-0652666919
Fax 39-0652665637
E-mail: fabianacecere@gmail.com
– Anna CERIBELLI, MD
Ospedale San Camillo de Lellis
Rieti | Italia
E-mail: aceribelli@yahoo.com [/EXPAND]
– Elisa CIBRARIO ROCCHIETTI
Data Manager presso S.S.D. Oncologia Polmonare
AOU San Luigi Gonzaga
Regione Gonzole, 10 – Orbassano (TO) | Italia
– Benedetta CRIDA, MD
Struttura Complessa di Pneumologia [EXPAND dettagli]
Ospedale Infantile Regina Margherita
Piazza Polonia, 94 – Torino | Italia
E-mail: bcrida@cittadellasalute.to.it [/EXPAND]
– Rossana CRITELLI
Data Manager presso S.S.D. Oncologia Polmonare
AOU San Luigi Gonzaga
Regione Gonzole, 10 – Orbassano (TO) | Italia
– Sara DE MICHELIS, MD
Fisiopatologia Respiratoria [EXPAND dettagli]
AOU San Luigi Gonzaga
Regione Gonzole, 10 – Orbassano (TO) | Italia
E-mail: sara_demichelis@yahoo.it [/EXPAND]
DISCOG – Università degli studi di Padova
Oncologia Medica 2 – Istituto Oncologico Veneto | Italia
E-mail: jessica.menis@iov.veneto.it [/EXPAND]
– Annamaria MICCIANZA, MD Ospedale Dario Camberlingo [EXPAND dettagli]
UOS di Oncologia nell’ambito della UOC di Medicina Interna
Via Madonna delle Grazie, strada provinciale per Ceglie Messapica
Francavilla Fontana (BR) | Italia
Tel.: +39-3357543812 / e-mail: miccianza@email.it[/EXPAND]
– Jelena STOJSIC
Institute for Lung Diseases and Tuberculosis [EXPAND dettagli]
Clinical Centre of Serbia
Department of Pathology
Visegradska 26 Belgrade – 11000 Belgrade | Serbia
Tel.: +381 11 357-04-25 / Tel.: +381 11 366-34-85 /
Cell.: +381 691 74-76-80 / e-mail: jelena.stojsic@kcs.ac.rs / dr.jelenastoj@sezampro.rs [/EXPAND]
– Marco TAGLIAMENTO, MD
Oncologia Medica 2
IRCCS Ospedale Policlinico San Martino
Università degli Studi di Genova
Largo Rosanna Benzi, 10 – Genova | Italia
E-mail: tagliamento.marco@gmail.com
– Maria Rosaria VALERIO, MD Policlinico Universitario “P.Giaccone” [EXPAND dettagli]
U.O. di Oncologia Medica
Dipartimento di Discipline Oncologiche
Via del Vespro, 129 – Palermo | Italia
Tel.: +39-091.6552761 / Fax: +39-091.6555611 / e-mail: valerionc17@libero.it [/EXPAND]
Oncogene driven Cancers: the new paradigm | Guarda il video introduttivo alle due giornate di Novembre 2019 a RomaOncogene driven Cancers: the new paradigm | Watch out the videoOncogene driven Cancers: the new paradigm